Cello Health PLC Board Changes (0545Y)
August 16 2018 - 7:30AM
UK Regulatory
TIDMCLL
RNS Number : 0545Y
Cello Health PLC
16 August 2018
FOR IMMEDIATE RELEASE 16 August 2018
Cello Health plc
("Cello", the "Company", or the "Group")
Board Changes
Cello Health plc (AIM: CLL), the global healthcare-focused
advisory Group, is pleased to announce the appointment, with
immediate effect, of two independent non-executive directors to the
Company's board of directors (the "Board"). The new Board members,
Clifford Tompsett and Jo LeCouilliard, both have extensive
experience in the pharmaceutical industry.
Clifford Tompsett was until recently a senior partner at
PriceWaterhouseCoopers LLP ("PwC"), with responsibility for the
firm's global cross border IPO practice. For a number of years
Clifford led the firm's UK and European activities in the
pharmaceutical sector, advising on many of the large deals in the
industry. He was at PwC for 38 years, and is a qualified chartered
accountant. Clifford will head the Board's Audit Committee and he
will also be the Company's Senior Independent Director.
Jo LeCouilliard was until recently at GlaxoSmithKline plc where
she held senior executive positions globally with roles in regions
including the United States and Asia. Jo has also held senior
hospital management positions at BMI Healthcare, and is currently a
non-executive director of Circassia Pharmaceuticals plc.
In line with the plans announced at the Annual General Meeting
on 10 May 2018, Paul Hamilton and Will David have both stood down
as non-executive directors with immediate effect, each having
served as members of the Board for more than a decade.
Mark Scott, CEO of Cello, said:
"Both Paul Hamilton and Will David have been non-executive
directors of the Company since its formation. Throughout that time,
they have helped the Board shape the Group into a leading
international business serving predominantly health orientated
clients. We are profoundly grateful for their efforts, and wish
them both the best for the future.
"I am delighted that the Group has secured the services of two,
highly experienced and capable new non-executive directors with
deep experience across the pharmaceutical industry. The Board very
much looks forward to working with Clifford and Jo as we shape the
future growth path for the Group."
Regulatory information
Full name (age) Current directorships: Previous directorships
/ partnerships (over
the last five years):
Clifford Peter Tompsett Dundas & Burgun Limited PricewaterhouseCoopers
(61) Hatton Farm Estates LLP
Limited
Kismet Acquisition
Limited
-------------------------- ------------------------------
Joanna Susan LeCouilliard Circassia Pharmaceuticals GlaxoSmithKline Pte.
(54) plc Ltd.
Glaxo Wellcome Manufacturing
Pte. Ltd.
General Healthcare
Group Ltd
Duke NUS Medical School
-------------------------- ------------------------------
Mr. Tompsett and Ms. LeCouilliard do not have any interests in
the ordinary shares of the Company.
There are no further disclosures to be made pursuant to Schedule
Two, paragraph (g) of the AIM Rules for Companies in respect of the
appointments of Mr. Tompsett and Ms. LeCouilliard.
Enquiries:
Cello Health plc 020 7812 8460
Mark Scott, Chief Executive
Mark Bentley, Group Finance Director
Cenkos Securities plc 020 7397 8900
Mark Connelly
Harry Hargreaves
Buchanan 020 7466 5000
Mark Court
Jamie Hooper
Sophie Wills
About Cello Health plc
Cello Health plc is a global healthcare-focused advisory Group
comprised of a set of leading clinical, commercial advisory and
digital delivery capabilities. Cello Health plc currently services
24 of the top 25 pharmaceutical clients globally, as well as a wide
range of biotech, diagnostics, devices and other key non-healthcare
clients.
Cello Health plc enables clients to commercialise and
differentiate their assets and drive brand success in ever more
complex global markets. The business delivers its services through
nearly 1,000 highly skilled professionals, utilising latest
thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in
the UK, USA, and Asia, with hub offices in New York City,
Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit:
https://cellohealthplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAEAAPKFAAPEFF
(END) Dow Jones Newswires
August 16, 2018 08:30 ET (12:30 GMT)
Cello Health (LSE:CLL)
Historical Stock Chart
From Apr 2024 to May 2024
Cello Health (LSE:CLL)
Historical Stock Chart
From May 2023 to May 2024